Company Overview of United Therapeutics Corporation
United Therapeutics Corporation, a biotechnology company, develops and commercializes products to address the unmet medical needs of patients with chronic and life-threatening diseases worldwide. The company’s product candidates include Remodulin, a continuously-infused formulation of the prostacyclin analogue treprostinil for subcutaneous and intravenous administration to diminish symptoms associated with exercise in pulmonary arterial hypertension (PAH) patients; Tyvaso, an inhaled formulation of treprostinil to enhace the exercise ability in PAH patients; Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; and Adcirca, a once-daily PDE-5 inhib...
1040 Spring Street
Silver Spring, MD 20910
Founded in 1996
Key Executives for United Therapeutics Corporation
Founder, Chairman of the Board and Chief Executive Officer
Total Annual Compensation: $1.1M
Chief Financial Officer and Treasurer
Total Annual Compensation: $380.1K
Executive Vice President, General Counsel and Corporate Secretary
Total Annual Compensation: $760.2K
Total Annual Compensation: $925.0K
Compensation as of Fiscal Year 2015.
United Therapeutics Corporation Key Developments
United Therapeutics Mulls Acquisitions
Feb 23 17
United Therapeutics Corporation (NasdaqGS:UTHR) is looking for acquisitions. Chief Executive Officer, Martine Rothblatt, commented " We still looking at potential mergers and acquisitions to help grow the company's revenue streams, but declined to discuss specifics. The company was more aggressive on research and development and business development in the second half of 2016. We are looking at opportunities that could use up substantially all of the borrowing authority or cash in the bank that we have right now. So we still would be very cautious about spending $1 billion plus on an acquisition."
United Therapeutics Corporation Reports Consolidated Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2016; Reports Impairment Charges for the Fourth Quarter Ended December 31, 2016
Feb 22 17
United Therapeutics Corporation reported consolidated earnings results for the fourth quarter and full year ended December 31, 2016. For the quarter, the company reported total revenue of $409.0 million compared to $404.9 million a year ago. Operating income was $174.2 million compared to $155 million a year ago. Income before income taxes was $171.5 million compared to $156 million a year ago. Net income was $110.3 million compared to $104.6 million a year ago. Diluted net income per share was $2.43 compared to $2.10 a year ago. Non-GAAP earnings were $187.2 million compared to $189.1 million a year ago. Diluted Non-GAAP earnings per share were $4.12 compared to $3.80 a year ago.
For the full year, the company reported total revenue of $1,598.8 million compared to $1,460.6 million a year ago. Operating income was $1,061.7 million compared to $699.0 million a year ago. Income before income taxes was $1,060.2 million compared to $1,044.4 million a year ago. Net income was $713.7 million compared to $651.6 million a year ago. Diluted net income per share was $15.25 compared to $12.72 a year ago. Non-GAAP earnings were $748.6 million compared to $631.7 million a year ago. Diluted Non-GAAP earnings per share were $16.00 compared to $12.33 a year ago.
For the fourth quarter ended December 31, 2016, the company reported impairment charges of $4.3 million.
United Therapeutics Corporation to Report Q4, 2016 Results on Feb 22, 2017
Feb 15 17
United Therapeutics Corporation announced that they will report Q4, 2016 results at 9:00 AM, Eastern Standard Time on Feb 22, 2017
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|